Angiogenese und Endometriose

Subscribe to RSS DOI: 10.1055/s-2004-822818 © Georg Thieme Verlag Stuttgart · New York Angiogenese und Endometriose Angiogenesis and EndometriosePublication History Publication Date: 27 August 2004 (online) Zusammenfassung Die Endometriose ist eine chronische Erkrankung der Frau im reproduktionsfähigen Alter, die Ähnlichkeiten zu malignen Tumorerkrankungen aufweist. Die medikamentöse Behandlung der endometrioseassoziierten Schmerzen sowie der Infertilität ist unbefriedigend. Es gibt Hinweise, dass die Neubildung von Blutgefäßen, die Angiogenese, eine wichtige Rolle bei der Endometriose spielt. Die Hemmung der Angiogenese könnte in Zukunft einen neuen viel versprechenden Therapieansatz darstellen, indem Angiogeneseinhibitoren als wirksame Ergänzungen bestehender Therapieschemata eingesetzt werden. Die detaillierte Erforschung der zugrunde liegenden Pathomechanismen ist notwendig, um eine Aussage über mögliche Indikation und Sicherheit dieser Substanzen sowie deren Auswirkung auf das reproduktive System der Frau treffen zu können. Abstract Endometriosis is considered a chronic disease of women during their reproductive phase, which resembles many signs of malignancy. So far, therapeutic options for endometriosis-associated pain and infertility are unsatisfactory and often lead to recurrence of disease after termination of treatment. Angiogenesis seems to play an important role in the pathogenesis of endometriosis. The use of angiogenesis inhibitors may add an important new tool to well-established treatment schedules. Therefore, it is very important to thoroughly investigate the role of angiogenesis in endometriosis with respect to the female reproductive system. Schlüsselwörter Angiogenese - Endometriose - VEGF - FGF - MMP - Angiogenese-Inhibitoren Key words Angiogenesis - endometriosis - VEGF - FGF - MMP - inhibitors of angiogenesis Literatur - 1 Rawson J M. Prevalence of endometriosis in asymptomatic women. J Reprod Med. 1991; 36 513-515 - 2 Galle P C. Clinical presentation and diagnosis of endometriosis. Obstet Gynecol Clin North Am. 1989; 16 29-42 - 3 Sampson J. Peritoneal endometriosis due to the menstrual dissemination of endothelial tissue into the peritoneal cavity. Am J Obstet Gynecol. 1927; 14 422-469 - 4 Leyendecker G, Herbertz M, Kunz G, Mall G. Endometriosis results from the dislocation of basal endometrium. Hum Reprod. 2002; 17 2725-2736 - 5 Ebert A D. Endometriose. Ein Wegweise für die Praxis. De Gruyter, Berlin, New York 2003; pp 104 - 6 Ajossa S, Mais V, Guerriero S, Paoletti A M, Caffiero A, Murgia C, Melis G B. The prevalence of endometriosis in premenopausal women undergoing gynecological surgery. Clin Exp Obstet Gynecol. 1994; 21 195-197 - 7 Farquhar C M. Extracts from the “clinical evidence”. Endometriosis. Bmj. 2000; 320 1449-1452 - 8 Kobayashi H. Invasive capacity of heterotopic endometrium. Gynecol Obstet Invest. 2000; 50 26-32 - 9 Ueki M. Histologic study of endometriosis and examination of lymphatic drainage in and from the uterus. Am J Obstet Gynecol. 1991; 165 201-209 - 10 Obata K, Hoshiai H. Common genetic changes between endometriosis and ovarian cancer. Gynecol Obstet Invest. 2000; 50 39-43 - 11 Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000; 60 7052-7056 - 12 Thomas E J, Campbell I G. Evidence that endometriosis behaves in a malignant manner. Gynecol Obstet Invest. 2000; 50 2-10 - 13 Tamura M, Fukaya T, Murakami T, Uehara S, Yajima A. Analysis of clonality in human endometriotic cysts based on evaluation of X chromosome inactivation in archival formalin-fixed, paraffin-embedded tissue. Lab Invest. 1998; 78 213-218 - 14 Yoshikawa H, Jimbo H, Okada S, Matsumoto K, Onda T, Yasugi T, Taketani Y. Prevalence of endometriosis in ovarian cancer. Gynecol Obstet Invest. 2000; 50 11-17 - 15 Chen Z, Malhotra P S, Thomas G R, Ondrey F G, Duffey D C, Smith C W, Enamorado I, Yeh N T, Kroog G S, Rudy S, McCullagh L, Mousa S, Quezado M, Herscher L L, Van Waes C. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res. 1999; 5 1369-1379 - 16 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1 27-31 - 17 McLaren J. Vascular endothelial growth factor and endometriotic angiogenesis. Hum Reprod Update. 2000; 6 45-55 - 18 Shaw R W. Treatment of endometriosis. Lancet. 1992; 340 1267-1271 - 19 Oosterlynck D J, Meuleman C, Sobis H, Vandeputte M, Koninckx P R. Angiogenic activity of peritoneal fluid from women with endometriosis. Fertil Steril. 1993; 59 778-782 - 20 Koninckx P R, Kennedy S H, Barlow D H. Endometriotic disease: the role of peritoneal fluid. Hum Reprod Update. 1998; 4 741-751 - 21 Boehm T, Folkman J, Browder T, O'Reilly M S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390 404-407 - 22 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86 353-364 - 23 Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997; 18 4-25 - 24 Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol. 1999; 237 41-57 - 25 Dvorak H F, Brown L F, Detmar M, Dvorak A M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995; 146 1029-1039 - 26 Charnock-Jones D S, Sharkey A M, Rajput-Williams J, Burch D, Schofield J P, Fountain S A, Boocock C A, Smith S K. Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biol Reprod. 1993; 48 1120-1128 - 27 Taylor R N, Lebovic D I, Mueller M D. Angiogenic factors in endometriosis. Ann N Y Acad Sci. 2002; 955 89-100 - 28 Klagsbrun M, Moses M A. Molecular angiogenesis. Chem Biol. 1999; 6 R 217-R 224 - 29 Klagsbrun M, D'Amore P A. Regulators of angiogenesis. Annu Rev Physiol. 1991; 53 217-239 - 30 Huang J C, Papasakelariou C, Dawood M Y. Epidermal growth factor and basic fibroblast growth factor in peritoneal fluid of women with endometriosis. Fertil Steril. 1996; 65 931-934 - 31 Di Blasio A M, Centinaio G, Carniti C, Somigliana E, Vigano P, Vignali M. Basic fibroblast growth factor messenger ribonucleic acid levels in eutopic and ectopic human endometrial stromal cells as assessed by competitive polymerase chain reaction amplification. Mol Cell Endocrinol. 1995; 115 169-175 - 32 Ferriani R A, Charnock-Jones D S, Prentice A, Thomas E J, Smith S K. Immunohistochemical localization of acidic and basic fibroblast growth factors in normal human endometrium and endometriosis and the detection of their mRNA by polymerase chain reaction. Hum Reprod. 1993; 8 11-16 - 33 Salamonsen L A, Woolley D E. Matrix metalloproteinases in normal menstruation. Hum Reprod. 1996; 11 (Suppl 2) 124-133 - 34 Kleiner D E, Stetler-Stevenson W G. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol. 1999; 43 S 42-S 51 - 35 Matrisian L M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 1990; 6 121-125 - 36 Sillem M, Prifti S, Neher M, Runnebaum B. Extracellular matrix remodelling in the endometrium and its possible relevance to the pathogenesis of endometriosis. Hum Reprod Update. 1998; 4 730-735 - 37 Chung H W, Lee J Y, Moon H S, Hur S E, Park M H, Wen Y, Polan M L. Matrix metalloproteinase-2, membranous type 1 matrix metalloproteinase, and tissue inhibitor of metalloproteinase-2 expression in ectopic and eutopic endometrium. Fertil Steril. 2002; 78 787-795 - 38 Ueda M, Yamashita Y, Takehara M, Terai Y, Kumagai K, Ueki K, Kanda K, Hung Y C, Ueki M. Gene expression of adhesion molecules and matrix metalloproteinases in endometriosis. Gynecol Endocrinol. 2002; 16 391-402 - 39 Sharpe-Timms K L, Cox K E. Paracrine regulation of matrix metalloproteinase expression in endometriosis. Ann N Y Acad Sci. 2002; 955 147-156 - 40 O'Reilly M S, Holmgren L, Shing Y, Chen C, Rosenthal R A, Moses M, Lane W S, Cao Y, Sage E H, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994; 79 315-328 - 41 Dabrosin C, Gyorffy S, Margetts P, Ross C, Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol. 2002; 161 909-918 - 42 Hazzard T M, Rohan R M, Molskness T A, Fanton J W, D'Amato R J, Stouffer R L. Injection of antiangiogenic agents into the macaque preovulatory follicle: disruption of corpus luteum development and function. Endocrine. 2002; 17 199-206 - 43 Klauber N, Rohan R M, Flynn E, D'Amato R J. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat Med. 1997; 3 443-446 - 44 Eder J P, Supko J G, Clark J W, Puchalski T A, Garcia-Carbonero R, Ryan D P, Shulman L N, Proper J, Kirvan M, Rattner B, Connors S, Keogan M T, Janicek M J, Fogler W E, Schnipper L, Kinchla N, Sidor C, Phillips E, Folkman J, Kufe D W. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol. 2002; 20 3772-3784 - 45 Calabrese L, Fleischer A B. Thalidomide: current and potential clinical applications. Am J Med. 2000; 108 487-495 - 46 Hayes E C, Rock J A. COX-2 inhibitors and their role in gynecology. Obstet Gynecol Surv. 2002; 57 768-780 - 47 Dawood M Y. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med. 1988; 84 23-29 - 48 Vane J R, Botting R M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med. 1998; 104 2S-8S - 49 Bensen W G, Fiechtner J J, McMillen J I, Zhao W W, Yu S S, Woods E M, Hubbard R C, Isakson P C, Verburg K M, Geis G S. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999; 74 1095-1105 - 50 Emery P, Zeidler H, Kvien T K, Guslandi M, Naudin R, Stead H, Verburg K M, Isakson P C, Hubbard R C, Geis G S. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet. 1999; 354 2106-2111 - 51 Ota H, Igarashi S, Sasaki M, Tanaka T. Distribution of cyclooxygenase-2 in eutopic and ectopic endometrium in endometriosis and adenomyosis. Hum Reprod. 2001; 16 561-566 - 52 Koike H, Egawa H, Ohtsuka T, Yamaguchi M, Ikenoue T, Mori N. Correlation between dysmenorrheic severity and prostaglandin production in women with endometriosis. Prostaglandins Leukot Essent Fatty Acids. 1992; 46 133-137 - 53 Masferrer R, Gomez C H, Karahalios D G, Sonntag V K. Efficacy of pedicle screw fixation in the treatment of spinal instability and failed back surgery: a 5-year review. J Neurosurg. 1998; 89 371-377 - 54 Form D M, Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med. 1983; 172 214-218 - 55 Koninckx P R, Meuleman C, Oosterlynck D, Cornillie F J. Diagnosis of deep endometriosis by clinical examination during menstruation and plasma CA-125 concentration. Fertil Steril. 1996; 65 280-287 - 56 Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature. 1996; 380 364-366 - 57 Pasqualini R, Arap W, McDonald D M. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med. 2002; 8 563-571 Priv.-Doz. Dr. med. Dr. phil. Andreas D. Ebert Deutsches Endometriose Kompetenz- und Experten-Netzwerk (DEKEN) · Frauenklinik und Poliklinik · Charité-Universitätsmedizin Berlin Campus Benjamin Franklin Hindenburgdamm 30 12203 Berlin Email: [email protected]